Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7296954 | 0.85 | GPR119 (0.63) | GPR119PDE3BPDE3APDE2A | |
| SCHEMBL11134908 | 0.77 | GPR119 (0.46) | GPR119PDE3BPDE3APDE2AAXL | |
| SCHEMBL11317688 | 0.76 | PDE3B (0.49) | GPR119PDE3BPDE3APDE2A | |
| SCHEMBL11283614 | 0.75 | MAPT (0.68) | GPR119PDE3BPDE3APDE2A | |
| SCHEMBL7296342 | 0.74 | PDE3B (0.61) | GPR119PDE3BPDE3A | |
| SCHEMBL16157002 | 0.74 | PDE3B (0.61) | GPR119PDE3BPDE3A | |
| SCHEMBL2593509 | 0.73 | GPR119 (1.00) | GPR119 | |
| SCHEMBL9686758 | 0.72 | PDE2A (0.62) | GPR119PDE3BPDE3APDE2A | |
| SCHEMBL11268997 | 0.72 | PDE3B (0.62) | GPR119PDE3BPDE3A | |
| SCHEMBL9686762 | 0.71 | GPR119 (0.66) | GPR119PDE3BPDE3APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119665-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-02-21 | — | — | US | disclosed |
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2007-09-06 | — | — | US | disclosed |
| US-7186734-B2 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1490343-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | Neurogen Corporation (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20040116424-A1 | Aryl imidazoles and related compounds as C5a receptor modulators | NEUROGEN CORPORATION | 2004-06-17 | — | — | US | disclosed |
| WO-2003082829-A1 | NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208048-A1 | New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators | C3AR1, C5AR1, C5AR2 | GPR119 285/4885PDE3B 811/4885PDE3A 1192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.